MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD

Phase 3 Completed 16 enrolled Dr. Leslie Morland Healing Breakthrough · collab Resilient Pharmaceuticals · collab San Diego Veterans Healthcare System · collab

NaSingle-groupOpen-labelTreatment

Summary

The goal of this pilot trial is to examine the preliminary effectiveness of MDMA-facilitated bCBCT for improving chronic PTSD and relationship functioning in a sample of veterans and their intimate partners seeking care within the VA San Diego Healthcare System.

Timeline

Start: 2023-10-06
Primary completion: 2025-11-14
Completion: 2025-11-14

Publications

Morland LA, Perivoliotis D, Wachsman TR, Alam A, Knopp K, Khalifian C, Ramanathan D, Chargin BE, Bismark AW, Glynn S, Stauffer C, Wagner AC. MDMA-assisted brief cognitive behavioral conjoint therapy for PTSD: Study protocol for a pilot study. Contemp Clin Trials Commun. 2024 May 24;40:101314. doi: 10.1016/j.conctc.2024.101314. eCollection 2024 Aug.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Midomafetamine	Unknown	40 mg	—
Subject	Midomafetamine	Unknown	80 mg	—
Subject	Midomafetamine	Unknown	100 mg	—

MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD

Summary

Timeline

Publications

Drugs

Indications